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Abstract 
Background: CD40L is implicated in atherosclerotic plaque formation.   
Objectives: We investigate prospective associations between circulating soluble CD40L 
and MI or stroke in an older general population cohort, accounting for established and 
novel cardiovascular risk factors. 
Methods: Baseline serum sCD40L was measured in incident MI (n=368) and stroke 
(n=304) cases and 2 controls per case, ‘nested’ in prospective UK studies of 4252 men and 
4286 women aged 60–79 years, sampled from general practices in Britain in 1998–2000, 
with 7-year follow-up for fatal and non-fatal MI and stroke.  
Results: Serum sCD40L was higher in smokers and negatively associated with lung 
function and positively associated with total cholesterol and markers of inflammation, but 
not with other established CVD risk factors.  Geometric mean sCD40L levels did not differ 
between MI cases and controls (6.28 pg/mL versus 6.09 pg/mL; p=0.5) or between stroke 
cases and controls (5.93 pg/mL versus 5.55 pg/mL, p = 0.1). There was no strong evidence 
for elevated risk of MI or stroke in multivariable models comparing participants in the top 
to those in the bottom third of sCD40L. Age-adjusted odds ratios were 1.39(95%CI 0.98, 
1.96) for MI and 1.16 (0.78, 1.73) for stroke. These attenuated to1.24 (95%CI 0.86, 1.79) 
and 1.18 (0.78, 1.78), respectively, after adjustment for established and novel CVD risk 
factors. 
Conclusions: Serum sCD40L is associated with other inflammatory markers but is not 
itself a strong independent risk marker for either stroke or MI. 
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Introduction  
Associations between levels of circulating inflammatory markers CRP, fibrinogen and IL-6 
and raised risks of CHD onset have been demonstrated in meta-analyses, although their 
causal basis remains debated[1-3].   Activated T lymphocytes, vascular endothelial cells, 
smooth muscle cells and macrophages all play a role in mediating expression of IL-6 and 
other circulating inflammatory markers associated with CHD risk[4].  Furthermore cell 
membrane interactions between leucocytes within developing rupture-prone atheromatous 
plaques, mediated by receptors such as the CD40 / CD40 ligand dyad (CD40L), may play a 
key role in atherothrombosis. As such, CD40L–CD40 interactions between T-cells and 
multiple lineages of antigen presenting cells may lead to plaque rupture and triggering of 
acute coronary events, during which platelet expression of the CD40/CD40L dyad may be 
exacerbated[5].   
Membrane-bound CD40L (mCD40L) can be sequestered into the circulation as soluble 
CD40L (sCD40L) by a poorly defined proteolytic process following T-cell activation. The 
biology of sCD40L is currently poorly understood. Nonetheless it has been suggested that 
because of the potential role of CD40L–CD40 interactions in plaque rupture, sCD40L 
levels will be positively associated with myocardial infarction (MI) and stroke. 
 
Elevated serum sCD40L levels have been observed in patients with unstable angina [6] 
compared to stable angina or controls, and in the circulation of patients with acute coronary 
syndrome (ACS) compared to controls with chest pain but no ST elevation [7].  Data from 
cross-sectional and prospective clinical studies suggest that elevated circulating sCD40L 
levels predict incident CVD events in patients with prevalent vascular disease [6-11].   One 
previous small study of healthy women reported an association between circulating levels 
sCD40L and CVD risk[12]. 
 
We therefore study the associations between sCD40L and incident MI and stroke in a 
cohort of men and women aged 60-79 years, drawn from across Britain, followed up for 
CVD events and mortality for 6-8 years; longer than previous studies.  We investigate the 
hypothesis that higher levels of circulating sCD40L are related to raised risks of incident 
MI and stroke in later adult life, and whether associations vary by age, gender or presence 
of pre-existing CVD.  
 
Methods 
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In 1998-2000, 4252 men from a single General Practice in each of 24 British towns who 
were already participating in a prospective study of CVD were examined at age 60-79 
years (response rate 77%)[13].  In 1999-2001, a parallel study of 4286 women of the same 
age and in the same Practices was established, omitting two study towns (Dewsbury and 
Maidstone) and adding another (Bristol), response rate 60%[14].  In both studies, nurses 
administered questionnaires, made physical measurements (weight, height and seated blood 
pressure), recorded an ECG and collected fasting venous blood samples, from which serum 
was stored at ≤-70oC for subsequent analysis of lipids, hemostatic and inflammatory 
markers as described elsewhere [1;13-15]. Soluble CD40L (ng/mL) was measured in 2007 
by researchers blinded to case-control status of samples, using a commercially available 
sandwich ELISA (R&D Systems, Oxon, UK), intra-assay variation was <5% and inter-
assay variation was <10%.  In two study towns, sCD40L was measured in 138 men in 1996 
and again in 2000, to enable intra-individual comparisons of values over time [16]. 
Participants completed detailed questionnaires. Pre-existing CVD was defined from reports 
from General Practitioner, or self-report of MI or stroke at any questionnaire between 
1978-80 and 1998-2000 in men and in the baseline questionnaire (1999/2000) in women.  
Data on cigarette smoking, alcohol consumption, physical activity, own longest-held 
occupation (or husband’s occupation for non-married women, coded using the Registrar 
General’s classification) were self-reported. Use of antiplatelet medications (BNF codes 2.9), 
ace inhibitors (BNF code 2.5.5.1), beta blockers (BNF code 2.4), statins (BNF code 2.12) and oral 
anti-diabetic medications, (BNF codes 6.1.2) was self-reported.  Region of residence was 
recorded for women in 1998-2000 and for men at the start of their follow-up in 1978-80.  
Participants were followed-up for 6.25-8.5 years for mortality and cardiovascular 
morbidity, with a follow up loss of <2%.  Fatal cases were ascertained through National 
Health Service Central Registers from a death certificate: ICD-9 codes 410-414 for MI and 
ICD-9 codes 430-438 for stroke, indicating deaths with cerebrovascular disease as the 
underlying cause. Non-fatal MI or stroke was diagnosed using World Health Organisation 
diagnostic criteria based on reports from General Practitioners, supplemented by regular 
reviews of General Practice records [13;17]. Participants provided written informed 
consent to the investigation and ethical approval was provided by all relevant local research 
ethics committees. 
  
A nested case-control study was established within the cohort study, .  All participants 
(including those with pre-existing cardiovascular disease), were eligible for selection. All 
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390 new MI cases occurring between examination date (1998-2000) and June 2006 in men 
and between examination date (1999-2001) and September 2007 in women were selected.  
Two controls (totalling 780) were “frequency matched” to each case on town of residence, 
gender and age in 5-year bands. Controls were randomly selected from among subjects 
who survived to the end of the study free from incident CVD.  A separate nested case 
control study based on 324 cases of stroke and 648 controls was similarly established. The 
MI and stroke control populations did not overlap. Both case and control populations 
included prevalent MI or stroke but controls had no incident cases during follow-up.   
 
Statistical analyses 
Highly skewed variables were transformed using natural logarithms and baseline (age 60-
79 years) characteristics of the MI case and control populations were calculated (mean and 
standard deviation, median and IQR for skewed variables, or n (%) for categorical 
variables). Continuous variables were adjusted for gender, region of residence and age.  
Tertiles of sCD40L were defined in the MI control sample. Unmatched logistic regression 
sample with complete data on outcomes and confounding variables.  Regression models 
were adjusted for cardiovascular risk factors selected a priori: (i) gender, age and region of 
residence; (ii) smoking status (current, ex, never); (iii) history of diabetes, or CHD, social 
class (manual or non-manual), alcohol use (1-2 drinks/day or other) physical activity (more 
or less than 3 hours of moderate/ vigorous activity per week), systolic and diastolic blood 
pressure (SBP and DBP), body mass index (BMI), total and HDL cholesterol as continuous 
variables; (iv) CRP and IL-6. Logistic regression models of continuous sCD40L, log 
transformed to base 2 were used to assess the effect of a doubling of sCD40L level on MI.  
Differences in the sCD40L-CVD associations were tested using likelihood ratio (LR) tests 
for interactions by gender, age and pre-existing CVD.  With the 293 MI cases and 236 
stroke cases, we had 80% power to detect a relative risk of 1.68 in the top tertile of 
sCD40L compared to the bottom tertile, at the 5% statistical significance level, assuming 2 
controls per case. As a form of sensitivity analysis, the estimates sCD40L-CVD 
associations were corrected for regression dilution using Rosner’s method[18]; a regression 
dilution ratio was calculated in a subset of 138 men with sCD40L levels measured 4 years 
apart[16] and applied to the estimates sCD40L-CVD associations. 
 
Results 
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MI  
Of the 390 cases and 790 selected controls, 368 cases (270 men and 98 women aged on 
average 70.8 years) and 713 controls had data available on sCD40 levels. Baseline 
characteristics of MI cases and controls are shown in Table 1. MI cases had a higher 
prevalence of pre-existing CVD (MI or stroke) and diabetes than controls, were more likely 
to smoke cigarettes and less likely to be physically active or light drinkers (all p<0.02) and 
had higher mean SBP, total cholesterol, triglycerides, insulin, glucose, CRP, IL-6, 
fibrinogen, and white blood cell count, lower HDL cholesterol and forced expiratory 
volume (FEV1) and similar SEP, BMI and DBP.  Geometric mean serum sCD40L was 
similar in the MI cases and controls; 6.28 pg/mL (IQR 4.63, 8.73) compared to 6.09 pg/mL 
(IQR 4.36, 8.30), p(no difference)=0.5.   
Stroke 
sCD40L data were available for 304 of 324 stroke cases (194 men and 110 women, mean 
age 71.4 years) and 596 of 648 controls. Characteristics of stroke cases and controls are 
shown in Table 2.  Cases had higher prevalence of pre-existing CVD and current smokers 
than controls (both p<0.003), but similar SEP, alcohol use, physical activity and prevalence 
of pre-existing diabetes.  Cases had higher mean systolic and diastolic blood pressure, total 
cholesterol, IL-6 and white blood cell count, but lower FEV1 and similar BMI, HDL, 
triglyceride, insulin, glucose CRP and fibrinogen to controls.  Geometric mean serum 
sCD40L levels was similar in the stroke cases and the controls; 5.93 pg/mL (IQR 4.18, 
7.98) compared to 5.55 pg/mL (IQR 3.85, 7.71), p(no difference)=0.1. 
Baseline correlates of sCD40L  
Table 3 summarises the associations between sCD40L and other markers of CVD risk 
across thirds of the MI control population (the larger of the two control populations). 
sCD40L levels were higher in current than non-smokers, were inversely associated with 
FEV1 but positively associated with total cholesterol in the MI control population, but not 
in the stroke control population (Supplementary Table 1). In the control populations, 
sCD40L levels were also generally weakly positively associated with CRP, white blood 
cell count and fibrinogen levels.  There were not consistent associations between sCD40L 
levels and demographic or behavioural factors or established CHD risk factors such as BP 
or lipids, or with insulin and glucose.  Similarly there were not consistent associations 
between sCD40L levels in the control populations with use of antiplatelet medications, 
statins, ACE inhibitors, beta blockers and oral anti-diabetic medications (data not 
presented).   
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Association of sCD40L with risk of MI 
The odds ratio (OR) for MI associated with the highest compared to the lowest third of 
sCD40L and adjusted for age, gender and region of residence (Model 1) was 1.39 (95%CI 
0.98, 1.96), with no evidence of a linear trend across the tertiles (p=0.26) (Table 3). Further 
adjustments for cigarette smoking (Model 2), established risk factors (Model 3) and for IL-
6 and CRP (Model 4) attenuated the association somewhat.  No strong evidence of 
association with MI was found when sCD40L was analysed as a continuous variable (Table 
3).  There was no evidence that sCD40L-MI associations varied by age, gender or by 
presence of pre-existing CVD (LR tests, all p>0.2). 
Association of sCD40L with risk of stroke 
There was no strong evidence of associations of  sCD40L with stroke in multivariate 
regression models for men and women together (Table 5) and there was no evidence for 
interaction by age or pre-existing CVD (LR tests p=0.8 and p=0.7 respectively).  However, 
there was some evidence that the association between sCD40L and stroke differed by 
gender (LR test p=0.02). For men, the OR for stroke associated with the highest compared 
to the lowest third of sCD40L and adjusted for age and region of residence (Model 1) was 
1.57 (95%CI 0.97, 2.54), p(linear trend across tertiles)=0.04 (Supplementary data Table 2). 
Further adjustments for cigarette smoking (Model 2), established risk factors (Model 3) and 
for IL-6 and CRP (Model 4) somewhat strengthened the ORs to 1.69 (1.02, 2.80), 
p(trend)=0.04.  A doubling of sCD40L level adjusted for age and region of residence 
(Model 1) was associated with an OR for stroke 1.30 (95%CI 1.01, 1.68), which was little 
changed by adjustments.  For women, the Model 1 OR was 1.03 (95% CI 0.70, 1.54). 
Extent of regression dilution  
A regression dilution ratio of 0.47(95%CI 0.24, 0.71) was calculated in a subset of 138 men 
with sCD40L levels measured 4 years apart and applied to ORs estimated in the full sample 
of men and women. After correction for regression dilution, the OR among participants in 
the top third of sCD40L compared with the lowest third and adjusted for age, gender and 
region, was 2.02 (95% CI 0.96, 4.19) for MI and 1.37 (95%CI 0.59, 3.21) for stroke. 
 
Discussion 
In this population-based study of older men and women, we found that serum sCD40L 
levels were associated with cigarette smoking status and with other inflammatory markers 
(CRP, white blood cell count and fibrinogen levels), but were not consistently associated 
with classical cardiovascular risk factors (health behaviours, lipids and blood pressure). 
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Our hypothesis that higher sCD40L levels would predict onset of either MI or stroke in 
older women and men  was not clearly supported. There was some evidence that higher 
levels of sCD40L were associated with increased risks of stroke in men. However, such 
interactions (subgroup analyses) often fail to replicate and further research is required 
before we could conclude that sCD40L is importantly associated with stroke in men but not 
women.   
 
Associations between sCD40L and CVD risk factors  
Our findings that sCD40L levels were associated with smoking[19;20] and with the 
inflammatory marker CRP[19;21] are in line with findings from some, but not all[22] other 
studies. Variations in the associations between sCD40L and inflammatory markers may be 
due to differences in age structure of study populations [22] as levels of inflammatory 
markers increase with age [23].  Our study of older adults adds to evidence accumulated 
from largely middle aged populations [7;8;12].   
 
Associations between sCD40L and CVD events 
Our study extends existing literature about associations between sCD40L and CVD.  
Firstly, it adds to the literature about generally healthy populations as it has more CVD 
cases and a longer follow-up period than the one previous case-control study.  It also has 
longer follow-up than previous studies of high risk groups and is able to account for many 
important confounding factors. Secondly ours is the first study to examine whether the 
associations between sCD40L and incident CVD differ by gender, age and presence of pre-
existing CVD.  Thirdly it provides estimates of associations corrected for within-person 
variability. Prior epidemiological [12] and experimental evidence[24] gave us reason to 
expect associations between sCD40L and CVD events, but we found no robust evidence 
for this. 
Studies examining the prognostic value of sCD40L levels for MI have mostly examined 
how sCD40L during or after an MI is related to subsequent events; some, but not all [25], 
report that raised sCD40L levels (eg above median or fourth quintile) are associated with 
raised risks of subsequent CHD or mortality [7;8].  The association between sCD40L and 
MI has been investigated in only one primarily healthy population (restricted to women), 
with only 130 cases, followed over 4 years; women with plasma sCD40L levels in the top 
5% of the control distribution (>3.71 ng/mL) had elevated relative risks of non-fatal MI or 
fatal ACS events[12].  However associations with CVD risk were not observed when less 
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extreme cut-points (eg median and quartiles) were used, this fits with our findings based on 
tertiles.  Associations might be observed in our data if more extreme comparison groups 
were used, although we did not see any evidence of associations across the whole sCD40L 
distribution when it was examined as a continuous covariate.  
The literature about sCD40L and stroke is sparse. A small study of patients with TIA or 
stroke found that the receptor CD40 was upregulated on monocytes, compared with 
controls at the time of event, but less so three months later[26].  One prospective study of 
high risk CVD patients reported that sCD40L levels above the median (>4.76 ng/ml) were 
predictive of subsequent stroke and MI as a composite endpoint and of stroke separately 
[11]. However, in a separate similarly powered study of AF patients which used a tertile 
analysis, plasma sCD40L had no strong association with risk of stroke [27]. 
Gender differences 
Ours is the first study to examine and report gender differences in associations between 
sCD40L and onset of CVD, so findings are exploratory and hypothesis generating.  There 
was some weak evidence that the association between sCD40L and stroke was stronger in 
men than in women.  Due to the limited number of cases in the gender stratified analysis, 
these findings must be interpreted cautiously and replicated.  
Strengths and Limitations    
Whilst our study is large in comparison with previous studies, being of sufficient size and 
statistical power to exclude an OR of 1.68 between top and bottom thirds of the sCD40L 
distribution, we cannot exclude a modest but potentially important association between 
sCD40L and CVD in healthy populations. Like other studies, we are limited by having only 
one measure of sCD40L, however, uniquely we were able to estimate intra-individual 
variability in serum sCD40L levels. Estimates suggested lower stability of sCD40L levels 
than several established risk factors [16]. After correction for within-person variability, the 
ORs were less conservative.  Although there was some imbalance between cases and 
controls with respect to smoking and diabetes and pre-existing CVD, we were able to 
account for these variables by adjusting for them in regression models.  The nested case-
control design required that controls survived to the end of the study which could introduce 
some bias (towards overestimating the results), however since observed adjusted 
associations were modest and not significant, any bias is unlikely to be problematic. 
Response rates were reasonably high and we do not believe that attrition would affect our 
estimate of the association between sCD40L and CVD, prior work on the men’s cohort 
suggests that non-attenders did not differ substantially from attenders[28] and we have 
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complete data from ONS death records and GP records on our outcome measures. Our 
results should therefore be generalisable to other healthy older adult populations. The 
validity of serum and plasma measures of sCD40L has been debated[5] as serum sCD40L 
may be subject to post-draw platelet degranulation but this may occur in both plasma and 
serum[29;30].  Although care has been taken with these serum samples, we cannot rule out 
the possibility of some degradation in sCD40L due to storage. To date no studies of pre-
analytical variability we are aware of have investigated this issue[31-33]. However, case 
and control populations have been treated in the same manner, and we have no reason to 
believe that any degradation in samples would be different in cases compared to controls. 
Furthermore, circulating serum concentrations of sCD40L in our stored samples from 
healthy men appear broadly similar to those observed in fresh serum[31;33].  Our 
observation that serum sCD40L is associated with markers of inflammation and smoking 
validates the supposition that it is indicative of inflammatory processes. 
 
Conclusions  
In our study of primarily healthy older men and women, circulating soluble sCD40L levels 
did not independently predict CVD events, although they were associated with other 
inflammatory markers which are CVD risk factors.  If other studies confirm these findings, 
it is unlikely that sCD40L will prove a useful diagnostic tool in predicting CHD and stroke 
risk in primarily healthy populations. . 
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Table 1. Baseline Characteristics (age 60-79) of the MI cases and controls: mean (SD) or 
n(%)
*
.
 
  
 MI Cases 
(n=368) 
MI Controls  
(n=713) 
Difference  
(p value) 
    
Demographic/questionnaire    
Age (years) 70.83 (5.46) 70.80 (5.43) Matched 
Male, n(%)  270 (73.4) 516 (72.4) Matched 
Northern region of residence, n(%)
†
  156 (42.4) 298 (41.8) Matched 
Non-manual occupation, n(%)
†
  155 (44.5) 325 (47.7) 0.333 
Prior evidence of CVD, n(%) 111 (30.2) 119 (16.7) <0.001 
History of diabetes, n(%) 66 (17.9) 76 (10.7) 0.001 
1-2 alcoholic drinks/day, n(%) 129 (38.2) 304 (46.2) 0.015 
Current smoker, n(%) 77 (20.9) 94 (13.2) 0.002 
Physical activity (inactive/occasional), n(%) 235 (66.4) 401 (58.8) 0.017 
    
Physical measurements    
Body Mass Index (Kg/m
2
)
‡||
 27.06 (4.23) 27.02 (3.96) 0.891 
Systolic blood pressure (mm/Hg)
‡§||
 153.89 (27.29) 148.69 (24.03) 0.001 
Diastolic blood pressure (mm/Hg)
‡§||
 83.78 (12.09) 83.28 (11.50) 0.512 
FEV1 (L/min)
‡||**
 2.15 (0.55) 2.23 (0.60) 0.028 
    
Lipids / Metabolic markers     
Total cholesterol (mMol/L)
‡
 6.24 (1.23) 6.09 (1.07) 0.032 
HDL cholesterol (mMol/L)
‡  1.32 (0.34) 1.42 (0.36) <0.001 
Triglyceride (mMol/L)
‡§#
 1.80 (1.31, 2.41) 1.58 (1.13, 2.09) <0.001 
Insulin (mU/L)
‡§#
 9.52 (6.09, 13.83) 8.14 (5.56, 11.23) <0.001 
Glucose (mMol/L)
‡§#
 6.16 (5.34, 6.38) 5.82 (5.31, 6.10) <0.001 
    
Inflammatory and hemostatic markers     
sCD40L(pg/mL)
‡#
 5.94  
(4.58, 8.72) 
5.82  
(4.37, 8.34) 
0.533 
C-Reactive Protein (mg/L)
‡#
 2.39 (1.05, 5.39) 1.77 (0.89, 3.62) <0.001 
IL-6(pg/ml)
‡§#
 2.97 (1.92, 4.07) 2.43 (1.61, 3.43) <0.001 
Fibrinogen(g/L)
‡§#
 3.46 (3.04, 3.95) 3.27 (2.84, 3.76) <0.001 
 17 
White cell count (^10
9
/L)
‡§#
 7.27 (6.03, 8.75) 6.80 (5.67, 7.97) <0.001 
*
Case-control sample is maximum available  
†
 reported in 1978-1980(age 40-59 years) for men and in 1998-2000 (age 60-79 years) for women 
‡ adjusted for gender, age and region of residence (Scotland, North, Midlands and South). 
§
 adjusted for time of day  
||
 adjusted for inter-observer variation 
# 
analysed as natural log transformed variable, geometric mean (IQR) reported on original scale.  
**
 adjusted for height squared 
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Table 2. Baseline Characteristics (age 60-79) of the stroke cases and controls: mean (SD) or 
n(%)
*
.  
 Stroke Cases 
(n=304) 
Stroke Controls  
(n=596) 
Difference  
(p value) 
    
Demographic/questionnaire    
Age (years) 71.36 (5.32) 71.39 (5.26) Matched 
Male, n(%)  194 (63.8) 377 (63.3) Matched 
Northern region, n(%)
†
  111 (36.5) 227 (38.1) Matched 
Non-manual occupation, n(%)
†
  125 (46.5) 263 (47.2) 0.632 
Prior evidence of CVD, n(%) 86 (28.3) 90 (15.1) <0.001 
History of diabetes, n(%) 43 (14.1) 73 (12.3) 0.422 
1-2 alcoholic drinks/day, n(%) 107 (38.8) 213 (38.4) 0.913 
Current smoker, n(%) 53 (17.4) 58 (9.8) 0.002 
Physical activity (inactive/occasional), n(%) 199 (71.7) 383 (66.8) 0.213 
    
Physical measurements    
Body Mass Index (Kg/m
2
)
‡||
 27.06 (4.33) 27.06 (4.09) 0.828 
Systolic blood pressure (mm/Hg)
‡§||
 154.32 (24.96) 149.37 (24.42) 0.005 
Diastolic blood pressure (mm/Hg)
‡§||
 84.98 (12.61) 82.45 (11.29) 0.002 
FEV1 (L/min)
‡||**
 2.09 (0.57) 2.23 (0.53) <0.001 
    
Lipids / Metabolic markers     
Total cholesterol (mMol/L)
‡
 6.13 (1.21) 6.32 (1.17) 0.023 
HDL cholesterol (mMol/L)
‡
 1.43 (0.40) 1.43 (0.36) 0.924 
Triglyceride (mMol/L)
‡§#
 1.64 (1.11, 2.32) 1.69 (1.23, 2.29) 0.468 
Insulin (mU/L) 
‡§#
 8.53 (5.61, 13.16) 7.96 (5.22, 11.60) 0.121 
Glucose (mMol/L)
‡§#
 6.05 (5.30, 6.17) 5.88 (5.29, 6.10) 0.105 
    
Inflammatory and hemostatic markers     
sCD40L (pg/ml)
‡#
 5.61 
(4.25, 7.93) 
5.28 
 (3.88, 7.69.) 
0.106 
C-Reactive Protein (mg/L)
‡#
 2.12 (1.04, 4.35) 1.92 (0.91, 4.10) 0.173 
IL-6(pg/ml)
‡§#
 2.83 (1.87, 4.14) 2.56 (1.65, 3.55) 0.021 
Fibrinogen(g/L)
‡§#
 3.35 (2.96, 3.85) 3.28 (2.88, 3.70) 0.092 
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White cell count (^10
9
/L)
‡§#
 7.22 (6.14, 8.60)  6.90 (5.78, 8.19) 0.011 
*
 case control sample is maximum available  
†
 reported in 1978-1980(age 40-59 years) for men and in 1998-2000 (age 60-79 years) for women 
‡ adjusted for gender, age and region of residence (Scotland, North, Midlands and South). 
§
 adjusted for time of day  
||
 adjusted for inter-observer variation 
#
analysed as natural log transformed variable, geometric mean (IQR) reported on original scale.  
**
 adjusted for height squared 
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Table 3. Association between sCD40L (tertiles) and cardiovascular risk factors in the MI 
control sample (n=713)  
 Low 
(0.41-4.88) 
N= 238 
Medium 
(4.89-7.46) 
N= 238 
High 
(7.46-20.37) 
n= 237 
Trend 
 
p-value
*
 
Demographic/questionnaire     
Age (years) 70.79 70.88  70.74 0.929 
Male, n(%)  161 (67.7) 178 (74.8) 177 (74.7) 0.087 
Northern region, n(%)
†
  87 (36.6) 109 (45.8) 102 (43.0) 0.152 
Non-manual occupation, n(%)
†
  109 (48.2) 123 (53.7) 93 (41.2) 0.132 
Evidence of CVD, n(%) 46 (19.3) 35 (14.7) 38 (16.0) 0.336 
History of diabetes, n(%) 30 (12.6) 24 (10.1)  22 (9.3) 0.242 
1-2 alcoholic drinks/day, n(%) 105 (51.8) 123 (55.4)  118 (54.1 0.631 
Current smoker, n(%) 16 (6.7) 29 (12.2) 49 (20.7) <0.001 
Physical activity (inactive/occasional), n(%) 134 (58.3) 134 (60.1) 133 (58.1) 0.969 
Physical measurements     
Body Mass Index (Kg/m
2
)
‡||
 27.07 27.00 26.99 0.759 
Systolic blood pressure (mm/Hg)
‡§||
 148.48 148.97 148.62 0.957 
Diastolic blood pressure (mm/Hg)
‡§||
 83.42 83.05 83.38 0.965 
FEV1 (L/min)
‡||**
 2.25 2.30 2.13 0.030 
Lipids / Metabolic markers     
Total cholesterol (mMol/L)
‡
 5.91 6.14 6.21 0.002 
HDL cholesterol (mMol/L)
‡
 1.41 1.42 1.43 0.571 
Triglyceride (mMol/L)
‡§#
 1.54 1.60 1.61 0.313 
Insulin (mU/L)
‡§#
 8.54 7.97 7.92 0.165 
Glucose (mMol/L)
‡§#
 5.87 5.79 5.81 0.575 
Inflammatory and hemostatic markers      
C-Reactive Protein (mg/L)
‡#
 1.53 1.81 2.00 0.008 
IL-6(pg/ml)
‡§#
 2.37 2.39 2.51 0.306 
Fibrinogen(g/L)
‡§#
 3.15 3.22 3.44 <0.001 
White cell count (^10
9
/L)
‡§#
 6.37 6.81 7.26 <0.001 
*
sample (n=713) MI controls with SCD40L value. Trend test adjusted for age, gender, region of residence  
†
 reported in 1978-1980(age 40-59 years) for men and in 1998-2000 (age 60-79 years) for women 
‡ adjusted for gender, age and region of residence (Scotland, North, Midlands and South). 
§
 adjusted for time of day  
 21 
||
 adjusted for inter-observer variation 
#
 geometric mean, p value from linear regression with ln(variable) 
**
 adjusted for height squared 
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Table 4. Odds Ratio (95% CI) of MI in men and women with sCD40L values in the highest 
compared to lowest tertile (n=902
*
)  
SCD40L MI 
cases 
MI  
controls 
OR (95% CI)  
Tertiles   Model 1 Model 2 Model 3 Model 4 
Range 
(pg/mL) 
      
7.46-20.37 113 198 1.39 (0.98, 1.96) 1.30 (0.91, 1.84)  1.26 (0.88, 1.81) 1.24 (0.86, 1.79) 
4.89-7.46 105 198 1.29 (0.91, 1.83) 1.26 (0.89, 1.79)  1.25 (0.87, 1.80) 1.26 (0.88, 1.82) 
0.41-4.88 84 204 1 1 1 1 
Total 302 600 p=0.263 p=0.531 p=0.674 p=0.813 
       
   OR (95%CI) 
 Doubling       
of 
SCD40L
†
 
302 
 
600 
 
1.11 (0.93, 1.33) 1.06 (0.88, 1.27) 
 
1.04 (0.86, 1.26) 
 
1.02 (0.85, 1.24) 
* 
complete case analysis sample. Tertiles based on control group. P value for test for trend over tertiles 
†
 OR of MI per 1 log2 increase in log 2(SCD40L) ie doubling of SCD40L 
Model 1= age, gender and region 
Model 2= model 1 + smoking  
Model 3= model 2+ SEP, alcohol, physical activity, history of diabetes, history of CVD, BMI, SBP, DBP, 
TC, HDL   
Model 4 =model 2 + IL-6 + CRP 
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Table 5. Odds Ratio (95% CI) of stroke in men and women with SCD40L values in the 
highest compared to lowest tertile (n=734)
*
 
SCD40L Stroke 
cases 
Stroke 
controls 
OR (95 % CI)  
Tertiles   Model 1 Model 2 Model 3 Model 4 
Range 
(pg/mL) 
   
 
   
6.98-28.61 78 161 1.16 (0.78, 1.73) 1.18 (0.80, 1.76) 1.20 (0.79, 1.80) 1.18 (0.78, 1.78) 
4.48-6.97 90 169 1.29 (0.88, 1.88) 1.29 (0.88, 1.89) 1.27 (0.85, 1.87) 1.25 (0.84, 1.85) 
0.32-4.47 69 167 1 1 1 1 
Total 237 497 p=0.132 p=0.118 p=0.121 p=0.139 
       
   OR (95% CI) 
Doubling       
of 
SCD40L
†
 
237 
 
497 
 
1.17 (0.95, 1.44) 
 
1.18 (0.96, 1.45) 
 
1.18 (0.96, 1.47) 
 
1.18 (0.95, 1.46) 
 
* 
complete case analysis sample. Tertiles based on control group. P value for test for trend over tertiles 
†
 OR of MI per 1 log2 increase in log 2(SCD40L) ie doubling of SCD40L 
Model 1= age, gender and region 
Model 2= model 1+ smoking 
Model 3= model 2+ SEP, alcohol, physical activity, history of diabetes, history of CVD, BMI, SBP, DBP, 
TC, HDL   
Model 4 =model 3 + IL-6 + CRP 
 
